The Chinese medical team’s Revolutionary CAR-T Therapy: Long-lasting asthma relief with a single injection

### 🚀 The Chinese medical team’s Revolutionary CAR-T Therapy: Long-lasting asthma relief with a single injection.!

asthma

📢 Exciting news from the world of medical science! The team led by Professor Peng Min at Tsinghua University has made a groundbreaking advancement in CAR-T cell therapy. Imagine a world where chronic diseases like allergic asthma can be managed with just a single injection. This could soon be a reality!

🌬 **Asthma: A Global Challenge**

Asthma is one of the most common respiratory diseases, affecting over 300 million people worldwide and causing approximately 250,000 deaths annually. Despite the availability of treatments, many patients require lifelong medication, which can be costly and burdensome.

💡 **The Breakthrough Study**

On May 27, 2024, the team published their findings in *Nature Immunology*. Their paper, titled *A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice*, introduces a novel CAR-T cell named 5TIF4. This engineered cell targets the factors that trigger allergic reactions. Remarkably, just one injection of 5TIF4 cells was enough to suppress signs and symptoms of allergic asthma in mice for an extended period.

🧬 **How Does It Work?**

Traditional therapies for chronic diseases often require repeated or lifelong administration. However, the 5TIF4 cells are designed to be long-lived and multifunctional. They can neutralize eosinophils (cells involved in allergic reactions) and block key pathways (IL-4 and IL-13 signaling) that drive asthma. This innovative approach not only targets the symptoms but also addresses the underlying causes of the disease.

🚧 **Challenges and Solutions**

While CAR-T therapy has revolutionized cancer treatment, applying it to non-cancerous diseases presents unique challenges:

1. **Targeting Non-Cancer Tissues**: Unlike tumors, affected organs like lungs in chronic diseases cannot be eliminated.

2. **Longevity of Therapy**: Chronic diseases are lifelong, necessitating long-lasting therapeutic cells.

3. **Safety**: Current CAR-T treatments often involve invasive procedures like chemotherapy, which are not suitable for chronic conditions.

Peng Min’s team overcame these hurdles by engineering CAR-T cells that do not require pre-treatment and can persist in the body, providing continuous protection against asthma.

💭 **Future Prospects**

The implications of this research are profound. If these results can be replicated in humans, we might see a new era where a single injection offers long-term relief from asthma. Moreover, the same principles could potentially be adapted to treat other diseases involving eosinophils and type 2 cytokines, such as allergies, atopic dermatitis, and eosinophilic esophagitis.

📰 *Nature Immunology* also highlighted this study in an article titled *CAR T cells put the brakes on asthma*, emphasizing the expanding scope of CAR-T therapy beyond cancer treatment.

🌟 **Conclusion**

This pioneering research by Tsinghua University marks a significant milestone in the fight against chronic diseases. With further clinical trials, we could be on the brink of a revolution in how we treat asthma and possibly other chronic conditions. Stay tuned for more updates on this exciting journey towards better health and wellness!

📸 Don’t forget to follow for more groundbreaking health news and updates!

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

#MedicalBreakthrough #CARTCellTherapy #AsthmaRelief #TsinghuaUniversity #HealthRevolution

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

6 months ago Solid tumor

Nature Medicine | New Hope! Chinese Medical Team Makes Breakthrough in Gastric Adenocarcinoma Treatment

Nature Medicine | **New Hope! Chinese Medical Team Makes Breakthrough in Gastric Adenocarcinoma Treatment**

Nature Medicine

In the medical field, unresectable advanced or metastatic gastric or gastroesophageal junction (#GEJ) adenocarcinoma has always been a daunting challenge. However, the latest research brings new hope to this field. #metastaticgastric #gastroesophagealjunction

**Innovative Treatment Brings New Hope**

The latest study published in *Nature Medicine* indicates that the drug Cadonilimab, in combination with chemotherapy, has significant efficacy and safety for patients with HER2-negative unresectable advanced or metastatic gastric or GEJ adenocarcinoma. This study, jointly conducted by scholars such as Jiafu Ji, Ziyu Li, and Lin Shen from Peking University, brings exciting news to this field.

**Key Findings**

Key findings of the study include:

– Cadonilimab in combination with chemotherapy has significant benefits for tumor response and survival, offering patients a ray of hope.

– The median overall survival reached 17.48 months in all patients, with higher benefits observed in patients with higher PD-L1 expression, reaching a median overall survival of 20.32 months in patients with PD-L1 CPS≥5.

– Even in patients with PD-L1 CPS<1, encouraging survival benefits were observed, with a median overall survival of 17.64 months.

– The drug demonstrated good safety profile, with treatment-related adverse events being manageable and tolerable.

**Dawning of Hope**

This study brings new hope to patients with gastric adenocarcinoma or GEJ adenocarcinoma. Regardless of PD-L1 expression, Cadonilimab in combination with chemotherapy exhibits encouraging clinical activity and manageable safety. This innovative treatment regimen holds the promise of fundamentally changing this life-threatening disease worldwide.

**Conclusion**

This groundbreaking research highlights the leading position of Chinese medical teams in the field of gastric adenocarcinoma treatment. With further research, we hope to see more innovative treatment options emerge, providing patients with more opportunities for survival and better quality of life. Let us look forward to the progress of medical science and bring more hope for health!

Want to know more Advanced medicine in China, You can send electronic copies or photos of genetic testing reports and diagnostic reports to the email address: doctor.huang@globecancer.com

or WhatsApp 137 1795 9070.

The Medical Department will contact you as soon as they receive the reports.

#GastricAdenocarcinomaTreatment #MedicalInnovation #HopeForHealth #gastriccarcinoma #gastriccancer #HER2 #Adenocarcinoma #cancertretment #chinesemedical #medicalscience #hope #hopeforhealth #NatureMedicine

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

6 months ago CAR-T , Solid tumor

New Breakthrough! Chinese Medical Team’s Remarkable Results with CLDN18.2 CAR-T Therapy for Pancreatic Cancer!

“New Breakthrough! Chinese Medical Team’s Remarkable Results with CLDN18.2 CAR-T Therapy for Pancreatic Cancer! 🎉”

Pancreatic Cancer

On May 25, 2024, the Journal of Clinical Oncology (JCO) published groundbreaking research by Professor Lin Shen’s team from Peking University Cancer Hospital on the application of CLDN18.2 CAR-T cell therapy for refractory metastatic pancreatic cancer, achieving impressive outcomes!

This study summarized the results of two phase I/Ib prospective clinical trials, involving a total of 24 advanced pancreatic cancer patients. Observations post-treatment revealed partial tumor shrinkage and significant reductions in CA19-9 levels in some patients, indicating a positive response. The research also demonstrated that CLDN18.2 CAR-T therapy not only showed significant efficacy in second- and third-line treatments but also exhibited promising potential in extending patient survival.

Assessment of treatment safety showed that the safety profile of CT041 cell therapy in this study was similar to previous findings, with no predefined dose-limiting toxicities observed. Treatment-related adverse events were mainly manageable, with cytokine release syndrome (CRS) and gastrointestinal adverse events typically mild and alleviated through proactive clinical management.

The results of this study demonstrate the potential and prospects of CLDN18.2 CAR-T cell therapy in CLDN18.2-positive metastatic pancreatic cancer patients. Significant reductions in CA19-9 levels, a disease control rate of 70.8%, and a significant extension of overall survival were observed, with treatment safety effectively controlled.

The publication of these research findings brings new hope for pancreatic cancer patients and provides important references for further research and clinical application of CLDN18.2 CAR-T cell therapy. We look forward to this breakthrough bringing gospel to more patients! 🌟

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China  for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

 #PancreaticCancer #CAR-TTherapy #MedicalBreakthrough

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

6 months ago CAR-T

Historic Moment! Chinese Medical Team Successfully Cures Diabetes Patient

**Historic Moment! Chinese Medical Team Successfully Cures Diabetes Patient**

Diabetes

In an exhilarating milestone moment, China’s medical technology has reached new heights! In a groundbreaking technological breakthrough, a Chinese medical team has successfully cured the world’s first case of type 2 diabetes through autologous regenerated pancreatic islet transplantation, marking a tremendous success in diabetes treatment! The patient has now been completely free from insulin for 33 months.

On May 7th, a reporter from The Paper News learned from the Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital) that on April 30th, Professor Yin Hao’s team from the hospital, in collaboration with Professor Cheng Xin’s team from the Chinese Academy of Sciences Molecular Cell Science Excellence Innovation Center, published their research findings online in the international academic journal “Cell Discovery” under the title “Treating a type 2 diabetic patient with impaired pancreatic islet function by personalized endoderm stem cell-derived islet tissue.” This is the first reported case internationally of successful treatment of severely impaired pancreatic islet function in diabetes using autologous stem cell-derived pancreatic islet transplantation.

**Miracle of Health Restoration**

This deeply touching story originates from a 59-year-old male who has suffered from diabetes for 25 years. After years of suffering, his diabetes had progressed to end-stage, facing numerous threats of complications. However, through the relentless efforts of Chinese scientists and doctors, he finally found the path to regaining his health.

**Technological Redemption**

Chinese scientists utilized cutting-edge stem cell technology to reprogram the patient’s own cells into endoderm stem cells, ultimately cultivating “seed cells” in vitro and reconstructing pancreatic islet tissue. This technology not only completely transformed the life of this patient but also brought new hope to diabetes patients worldwide.

**A New Era of Regenerative Medicine**

This is not just a technological breakthrough but also a revolutionary challenge to the medical community. The success of the Chinese medical team has opened a new door for diabetes patients worldwide, bringing endless possibilities.

**Future Prospects**

And this is just the beginning! Chinese scientists and doctors will continue to strive for further research, aiming to develop more advanced regenerative medical technologies and provide more effective treatment solutions for diabetes patients worldwide.

**The World Changes Because of China**

This feat not only signifies the rise of Chinese medicine but also serves as a model for China’s technological development. With its unique technological prowess and medical innovation, China is increasingly demonstrating its influence on the world stage.

Want more info about #pancreaticislet

doctor.huang@globecancer.com

WhatsApp: 137 1795 9070

#Diabetes #MedicalInnovation #RegenerativeMedicine #TechnologicalBreakthrough #ChinaPower

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

7 months ago CAR-T

AACR 2024/Breakthrough Chinese Research – Monotherapy for Late-stage #SolidTumors and #Lymphomas

AACR 2024/Breakthrough Chinese Research – Monotherapy for Late-stage #SolidTumors and #Lymphomas

AACR2024

#AACR2024

At the 2024 American Association for Cancer Research (#AACR) Annual Meeting, innovative drugs from China showed promising safety and preliminary efficacy in early clinical trials, attracting high interest from attending experts and researchers, showcasing the strength of #Chineseresearch teams in new drug development.

#TQB2916

A groundbreaking focus of cancer research is on #TQB2916, the latest #CD40 agonist antibody causing a stir in the medical field.

#CD40

 receptors, a member of the tumor necrosis factor receptor family, play a vital role in immune responses. TQB2916, a humanized IgG2 CD40 monoclonal antibody, has demonstrated CD40 activation and promising anti-tumor activity in preclinical studies. With its potential to revolutionize cancer treatment, TQB2916 is currently undergoing its first human study for late-stage solid tumors and lymphomas, led by the team at Tianjin Medical University Cancer Institute & Hospital.

#ECOG

Now, let’s delve into the details: Eligible patients, including those with an ECOG performance status of 0 or 1, adequate hematologic and organ function, and no response to standard treatments, are enrolled. TQB2916 is administered intravenously every 3 weeks until disease progression or unacceptable toxicity. The study utilizes a Bayesian Optimal Interval (BOIN) design to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D). The primary objectives are to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TQB2916.

#Realcase

From April 2022 to November 2023, a total of 18 patients with solid tumors and 2 with lymphomas underwent TQB2916 monotherapy and were assigned to 7 dose cohorts. Adverse events were observed, with the most common including lipase increase, amylase increase, lymphocyte count decrease, ALT increase, ALP elevation, AST elevation, hypoalbuminemia, and anorexia. However, most adverse events were manageable, primarily Grade 1 or 2 severity.

#Lymphomas

Of the 16 evaluated patients, 3 achieved stable disease according to immune RECIST criteria for solid tumors and LYRIC criteria for lymphomas. Pharmacokinetic analyses showed favorable performance, with no drug accumulation upon repeat dosing. Additionally, dose-dependent occupancy of CD40 receptors was detected, alongside peripheral B cell reduction and increased cytokine secretion.

#Conclusion

TQB2916 achieves CD40 engagement and immune activation through cytokine modulation. With its promising safety and efficacy profile, 200mg has been identified as the preliminary expansion dose. Studies exploring TQB2916 in combination with immune checkpoint inhibitors and/or other anti-cancer therapies are currently underway.

Stay tuned for more updates on this groundbreaking treatment!

You can send electronic copies or photos of genetic testing reports and diagnostic reports to the email address:

doctor.huang@globecancer.com

WhatsApp +86137 1795 9070

The Medical Department will contact you as soon as they receive the reports.

#CancerResearch #Immunotherapy #MedicalBreakthrough #AACR22024 #chinesemedical

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

7 months ago CAR-T

AACR 2024/Breakthrough in Treating Recurrent or Metastatic Nasopharyngeal Carcinoma by Chinese Medical Team

AACR 2024/Breakthrough in Treating Recurrent or Metastatic Nasopharyngeal Carcinoma by Chinese Medical Team

AACR 2024

We’re thrilled to share groundbreaking updates from the 2024 American Association for Cancer Research (AACR) Annual Meeting!

China’s innovative pharmaceuticals are making waves in early clinical trials, hinting at promising breakthroughs in cancer treatment!

At the forefront is the remarkable research on Treprilimumab, a monoclonal antibody, showcased by Prof. Ma Haiqiang and his team from Sun Yat-sen University Cancer Center.

Their pioneering work focuses on advancing treatments for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), a challenging form of cancer.

Treprilimumab, administered subcutaneously, has shown remarkable safety and preliminary efficacy when combined with Gemcitabine and Cisplatin (GP), earning FDA approval in October 2023 for first-line therapy in RM-NPC.

The team initiated the first human clinical trial to assess Treprilimumab’s pharmacokinetics in RM-NPC, aiming to establish optimal subcutaneous dosing regimens for future trials.

The study enrolled RM-NPC patients, confirmed histologically, and previously untreated systemically. Patients received Treprilimumab SC at 240mg Q3W, 360mg Q3W, or 480mg Q6W, in combination with GP for up to 6 cycles, followed by Treprilimumab SC monotherapy until disease progression, intolerable toxicity, or completion of 2 years of treatment. Tumor response was assessed by RECISTv1.1 criteria, with primary endpoints focusing on pharmacokinetics and secondary endpoints including safety, efficacy, and immunogenicity.

From November 24, 2022, to November 20, 2023, 38 patients were enrolled, with a median follow-up of 6.8 months. The median age was 49, with 73.7% male. Pharmacokinetic analysis revealed comparable exposure between Treprilimumab 360mg Q3W SC and 240mg Q3W IV in the first cycle. Overall response rates (ORR) were 100%, 92.3%, and 92.3% for the 240mg, 360mg, and 480mg groups, respectively. By November 20, 2023, 71.1% of patients experienced sustained remission, with no new safety concerns. Grade ≥3 adverse events (AEs) occurred in 76.3% of patients, with no fatalities. Immune-related AEs were reported in 36.8% of patients, with one case of grade ≥3.

These groundbreaking findings demonstrate comparable safety and clinical efficacy between Treprilimumab SC and IV formulations when combined with GP in treating RM-NPC patients. The exposure of Treprilimumab 360mg Q3W SC mirrors that of 240mg Q3W IV. Excitingly, Treprilimumab SC formulations are slated for Phase III clinical development, promising hope for enhanced cancer therapies!

Stay tuned for more updates on this game-changing research!

To assess whether the condition is suitable for Chinese Top level therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp: 137 1795 9070

Email: doctor.huang@globecancer.com

#AACR2024 #CancerResearch #InnovationInMedicine

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

8 months ago CAR-T

🎉💉 Exciting Breakthrough Alert! Chinese Medical Team Unveils Game-Changing mRNA Cancer Vaccine 🎉💉

🎉💉 Exciting Breakthrough Alert! Chinese Medical Team Unveils Game-Changing mRNA Cancer Vaccine 🎉💉

Advanced Science

 

Say hello to the future of cancer treatment! A groundbreaking mRNA cancer vaccine jointly developed by Chinese scientists has hit the spotlight, promising to elevate tumor suppression rates and extend survival periods.

🔬 What’s the Buzz? 🔬
Published in the prestigious journal “Advanced Science”, the research titled “All-Trans-Retinoic Acid-Adjuvanted mRNA Vaccine Induces Mucosal Anti-Tumor Immune Responses for Treating Colorectal Cancer” reveals a novel mRNA cancer vaccine. This vaccine, packaged with lipid nanoparticles (LNPs), delivers All-Trans-Retinoic Acid (ATRA) and mRNA, effectively stimulating mucosal immune responses in the intestines. Compared to conventional mRNA-LNP vaccines, this innovative approach significantly boosts tumor suppression and prolongs survival rates.

 

🩺 Why It Matters 🩺
Colorectal cancer ranks third in cancer incidence and second in mortality globally. Conventional treatments such as surgery, chemotherapy, and radiation often come with high recurrence rates. Enter cancer immunotherapy—the beacon of hope in the fight against colorectal cancer. Cancer vaccines, a vital component of immunotherapy, harness the body’s immune system to target and destroy cancer cells. With the recent success of mRNA vaccines for COVID-19, mRNA cancer vaccines have garnered immense attention for their potential to revolutionize cancer treatment.

 

🚀 The Breakthrough 🚀
The key lies in ATRA-LNP’s ability to induce cytotoxic T cells in the intestines, offering a promising therapeutic approach for colorectal cancer. In animal models, ATRA-LNP treatment led to a remarkable reduction in tumor growth and extended survival rates compared to conventional treatments. These findings underscore the potential of mRNA cancer vaccines, particularly in enhancing the treatment outcomes for colorectal cancer patients.

 

🌟 The Takeaway 🌟
With its ability to activate anti-tumor immune responses at mucosal surfaces, the novel mRNA cancer vaccine brings hope for improved outcomes in colorectal cancer treatment. ATRA incorporation into LNPs not only enhances mRNA delivery efficiency but also directs activated T cells towards the intestines, amplifying their anti-tumor effects. This study paves the way for a promising future in enhancing the efficacy of mRNA cancer vaccines against colorectal cancer.

 

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
Email: doctor.huang@globecancer.com,
WhatsApp: 137 1795 9070

#CancerResearch #MedicalBreakthrough #ImmunotherapyInAction #ColorectalCancerFighters #mRNA #CancerVaccine #vaccine #colorectal #colorectalcancer #cancerfighters #chinesemedical #cancertreatment #tumor

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

8 months ago Myeloma

Another BCMA CAR-T therapy for multiple myeloma hits the market in China! – 🔥Long-term efficacy 🔥

🌎Another BCMA CAR-T therapy for multiple myeloma hits the market in China!

    – 🔥Long-term efficacy 🔥

 

multiple myeloma

🌙China has made significant breakthroughs in the treatment of multiple myeloma with BCMA CAR-T therapy, attracting global attention. Recently, two fully human BCMA CAR-T therapies, Equecabtagene Autoleucel and Zevorcabtagene Autoleucel, have been approved for the treatment of relapsed/refractory multiple myeloma.⭐️

🌛 In terms of long-term efficacy, for patients with a CAR-T cell persistence of over one year, the percentage is 53.3% for Equecabtagene Autoleucel and 26.5% for Zevorcabtagene Autoleucel at six months’ persistence.⭐️

🌜The duration of CAR-T cell persistence has an impact on the survival outcome of multiple myeloma (MM) patients. Long-term follow-up data from the Lengend-2 study showed a significant improvement in the cumulative overall survival (OS) rate for RRMM patients with a CAR-T cell persistence of over 280 days compared to patients with a persistence of less than 280 days. Therefore, 280 days of persistence is a critical threshold for improving clinical outcomes.⭐️

✨The median persistence for Zevorcabtagene Autoleucel is 77 days, while for Equecabtagene Autoleucel, it is 419 days, far exceeding the critical threshold. It is expected to improve the OS of MM patients.⭐️

🌤From a clinical perspective, both therapies demonstrate a trend of improving long-term efficacy over time.

The complete response (CR) rate at six months of follow-up is 54.8% for Equecabtagene Autoleucel and 35.0% for Zevorcabtagene Autoleucel.⭐️

🌝At a median follow-up of around nine months, the registered clinical data from China shows a CR rate of ≥74.2% for Equecabtagene Autoleucel and 45.1% for Zevorcabtagene Autoleucel.⭐️

🌞During the 2023 IMS conference, Equecabtagene Autoleucel presented the latest long-term follow-up data, revealing a further increase in the CR rate to 82.4% at a median follow-up of 18.07 months.⭐️

☀️The efficacy data following a median follow-up of nine months for Zevorcabtagene Autoleucel in the registered clinical trial LUMMICAR-1 Phase 2 study has not been publicly disclosed.

China’s breakthroughs in CAR-T cell therapy are remarkable. It not only provides new treatment options for multiple myeloma patients but also demonstrates China’s strength in medical research and innovation. It brings hope and possibilities for improving patients’ survival and quality of life.⭐️

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: 137 1795 9070

Email: doctor.huang@globecancer.com

#BCMACART #MultipleMyeloma #Innovation #CART #CARTTherapy #chinesemedical

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

8 months ago Myeloma

Another BCMA CAR-T therapy for multiple myeloma hits the market in China! – Short-term efficacy

Another BCMA CAR-T therapy for multiple myeloma hits the market in China!

– Short-term efficacy

multiple myeloma

China  CAR-T therapy

    In recent years, CAR-T cell therapy has achieved tremendous success in treating hematologic malignancies. Over the past 11 years, China has seen a surge in clinical trials evaluating the safety and efficacy of CAR-T therapy. China has now surpassed the United States as a major force in CAR-T clinical research.

In the field of multiple myeloma (MM),

    China has gained regulatory approval from the NMPA for two fully human BCMA CAR-T therapies for the treatment of relapsed/refractory MM (R/R MM). These therapies are Equecabtagene Autoleucel and Zevorcabtagene Autoleucel.

BCMA

    While both therapies target the same BCMA and share a common co-stimulatory domain, there are some fundamental differences between them. Zevorcabtagene Autoleucel includes patients with stable disease after previous treatment, whereas Equecabtagene Autoleucel focuses on patients with relapsed or progressive MM.

Looking at the short-term efficacy

    The median time to peak CAR-T cells in peripheral blood is 12 days for Equecabtagene Autoleucel and 14 days for Zevorcabtagene Autoleucel. This indicates that the former can rapidly exert its effect, potentially laying the foundation for achieving clinical remission faster and better.

Clinical trial results seem to support this notion, with Equecabtagene Autoleucel showing a median time to response (TTR) of 15 days, compared to 29 days for Zevorcabtagene Autoleucel. At the 3-month follow-up, the complete remission rates were 40.3% for Equecabtagene Autoleucel in the registered clinical trial FUMANBA-1 1b/2 phase, surpassing the rate of 28.3% observed in the registered clinical trial LUMMICAR-1 phase 2 for Zevorcabtagene Autoleucel.

It’s worth noting that the infusion dose for Equecabtagene Autoleucel is 1×106 cells/kg, while the total infusion dose for Zevorcabtagene Autoleucel is 150×106 cells, which translates to double the dose of Equecabtagene Autoleucel for patients with a weight of 70kg-75kg. Additionally, the reinfusion dose for Zevorcabtagene Autoleucel is not fixed and needs to be increased to 1.8×108 cells for patients weighing ≥80kg.

With the increasing availability of these groundbreaking BCMA CAR-T therapies, the landscape of multiple myeloma treatment continues to expand, offering more possibilities and choices.

To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: 137 1795 9070

Email: doctor.huang@globecancer.com

#BCMACART #MultipleMyeloma #Innovation #CART #CARTTherapy #chinesemedical Advanced Medicine in China

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

11 months ago CAR-T

Breakthrough CAR-T Cell Therapy for R/R B-Cell ALL: A Game-Changer in Chinese Medical Innovation

Breakthrough CAR-T Cell Therapy for R/R B-Cell ALL: A Game-Changer in Chinese Medical Innovation

ALL- Acute Lymphoblastic Leukemia

The Fourth China Hematology Development Conference – CAR-T Frontier Forum and the First CAR-T Cell Immunotherapy Summit (JCIS), held on January 5, 2024, in Tianjin.

 

Potential Best-in-Class: Inaticabtagene Autoleucel Redefining Long-term Outcomes for R/R B-ALL

 

Professor Ma Jun from the Harbin Institute of Hematology and Oncology shared notable progress in immunotherapy and cell treatment for Chinese ALL. Previously, the overall complete response (CR) rate for adult R/R ALL treatment in China was approximately 40%, with a mere 11% 3-year survival rate. The introduction of CAR-T cell therapy has been a paradigm shift, altering the long-term outcomes for R/R B-ALL patients.

Inaticabtagene Autoleucel demonstrates superior efficacy:

Higher overall response rates (ORR) at 3 months and beyond, with median duration of response (DOR) and overall survival (OS) surpassing other products.

Patients treated with Inaticabtagene Autoleucel exhibit similar long-term benefits in OS, whether or not they undergo subsequent transplantation.

 

Inaticabtagene Autoleucel boasts enhanced safety:

Lower incidence rates of grade 3 cytokine release syndrome (CRS), grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS), and infusion-related mortality compared to other CAR-T products.

 

Moreover, in minimal residual disease-positive (MRD+) B-ALL patients, CAR-T cell therapy has shown significant progress. It eradicates MRD, improves survival rates, and may serve as a first-line consolidation therapy for CR patients, aiding in:

 

Higher remission rates

Reduced transplant requirements, mitigating transplant-related complications

Maintenance of long-term remission for those unsuitable for allo-HSCT or unwilling to undergo it

 

Improved overall survival

Lower intensity and duration of intensive chemotherapy, leading to shorter treatment times and enhanced compliance.

 

The Future Outlook: Believing in the potential of CAR-T cell therapy, it is anticipated that this innovative treatment will extend hope to currently incurable diseases such as solid tumors and brain tumors. The strides made in Chinese medical innovation, exemplified by Inaticabtagene Autoleucel, signal a promising future for the global landscape of CAR-T cell therapy.

 

#CARTRevolution #InaticabtageneAutoleucel #HematologicCancerTherapy #ClinicalBreakthrough #ChinaHematologyConference #JCIS #BAllTreatment #MedicalAdvancements #CancerResearch #TreatmentInnovation #InaticabtageneAutoleucel #Autoleucel #ChineseCART #CARTTherapy #cancer #Bloodcancer #MedicineinCHINA #Medicaltourismo #Advancedmedicine #cancertherapy #leukemia